Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Targeting the function of the HER2 oncogene in human cancer therapeutics.

Moasser MM.

Oncogene. 2007 Oct 11;26(46):6577-92. Epub 2007 May 7. Review.

2.

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.

Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T.

J Thorac Oncol. 2007 May;2(5):430-9.

3.
4.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA.

Science. 2007 May 18;316(5827):1039-43. Epub 2007 Apr 26.

5.

Insights from transgenic mouse models of ERBB2-induced breast cancer.

Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ.

Nat Rev Cancer. 2007 May;7(5):389-97. doi: 10.1038/nrc2127. Epub 2007 Apr 19. Review.

PMID:
17446858
6.

Epidermal growth factor receptor mutations in lung cancer.

Sharma SV, Bell DW, Settleman J, Haber DA.

Nat Rev Cancer. 2007 Mar;7(3):169-81. Review.

PMID:
17318210
7.

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA Jr.

Ann Oncol. 2007 Apr;18(4):752-60. Epub 2007 Feb 22.

PMID:
17317677
8.

A dimerization hierarchy in the transmembrane domains of the HER receptor family.

Duneau JP, Vegh AP, Sturgis JN.

Biochemistry. 2007 Feb 20;46(7):2010-9. Epub 2007 Jan 25.

PMID:
17253768
9.

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM.

Nature. 2007 Jan 25;445(7126):437-41. Epub 2007 Jan 7.

10.

Update on epidermal growth factor receptor mutations in non-small cell lung cancer.

Riely GJ, Politi KA, Miller VA, Pao W.

Clin Cancer Res. 2006 Dec 15;12(24):7232-41. Review.

11.

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.

Cohenuram M, Saif MW.

Anticancer Drugs. 2007 Jan;18(1):7-15. Review.

PMID:
17159497
12.

Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival.

Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL.

J Neuropathol Exp Neurol. 2006 Dec;65(12):1181-8.

PMID:
17146292
13.

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.

14.

Cetuximab in the treatment of head and neck cancer.

Bernier J.

Expert Rev Anticancer Ther. 2006 Nov;6(11):1539-52. Review.

PMID:
17134359
15.
16.

ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas.

Jeong EG, Soung YH, Lee JW, Lee SH, Nam SW, Lee JY, Yoo NJ, Lee SH.

Int J Cancer. 2006 Dec 15;119(12):2986-7. No abstract available.

17.

Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer.

Schiffer HH, Reding EC, Fuhs SR, Lu Q, Piu F, Wong S, Littler PL, Weiner DM, Keefe W, Tan PK, Nash NR, Knapp AE, Olsson R, Brann MR.

Mol Pharmacol. 2007 Feb;71(2):508-18. Epub 2006 Sep 12.

18.

EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.

Choi SH, Mendrola JM, Lemmon MA.

Oncogene. 2007 Mar 8;26(11):1567-76. Epub 2006 Sep 4.

PMID:
16953218
19.

Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.

Gallo RM, Bryant I, Fry R, Williams EE, Riese DJ 2nd.

Biochem Biophys Res Commun. 2006 Oct 13;349(1):372-82. Epub 2006 Aug 18.

20.

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.

Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, Park F, Haley JD, Gibson N, Sliwkowski MX.

Cancer Res. 2006 Aug 15;66(16):8163-71.

Supplemental Content

Support Center